Investigating Mitochondrial Viscosity in Ferroptosis‐Mediated Drug‐Induced Liver Injury using a Double‐Targeted Strategy
Source abstract
Abstract
Abstract Investigating mitochondrial viscosity in ferroptosis‐mediated drug‐induced liver injury (DILI) is helpful for the reliable diagnosis and therapy of liver injury. Nevertheless, mitochondrial function and membrane potential may be impaired in the occurrence and development of DILI, so accurately monitoring viscosity changes remains a difficult task. Considering the presence of high expression of mitochondrial uncoupling protein 2 (UCP2) in liver injury, a new near‐infrared fluorescent probe (named FTZ‐2) is presented to investigate the tanglesome relationships between mitochondrial viscosity and ferroptosis‐mediated DILI by introducing a mitochondrial double‐targeted strategy that combined electrostatic reaction and probe–protein docking. The newly synthetized FTZ‐2 is highly selective to environmental viscosity in the presence of reactive species. Owing to its favorable cytotoxicity and mitochondrial localization characteristics, FTZ‐2 is used to monitor viscosity variations in ferroptosis cells and ferroptosis‐mediated DILI mice. The reduction of fluorescence signals indicated that ferrostatin‐1, glutathione, and N‐acetyl‐L‐cysteine can alleviate liver injury. Notably, the high expression of UCP2 is also discovered in the liver of ferroptosis mice and ferroptosis‐mediated DILI mice. Taken together, this work demonstrated a double‐targeted strategy for the early diagnosis and evaluation of liver injury through mitochondrial viscosity variations and contributed to the improvement of the therapeutic effect against liver injury.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Ferroptosis and cancer prognosis · Sulfur Compounds in Biology · Molecular Sensors and Ion Detection
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Chemistry and Chemical Engineering University of Jinan Jinan 250022 P. R. China
Department of Chemistry and Nanoscience Ewha Womans University Seoul 03760 South Korea
Graduate Program in Innovative Biomaterials Convergence Ewha Womans University Seoul 03760 South Korea
Funding
National Natural Science Foundation of China · Natural Science Foundation of Shandong Province · National Research Foundation of Korea
References (62)
Show source-provided references
1. 10.1038/s41572-019-0105-010.1038/s41572-019-0105-0 ↗
2. 10.1016/j.ejim.2021.10.03510.1016/j.ejim.2021.10.035 ↗
3. 10.1097/HEP.000000000000062810.1097/HEP.0000000000000628 ↗
4. 10.1002/hep.3042210.1002/hep.30422 ↗
5. 10.1016/j.chom.2023.04.00210.1016/j.chom.2023.04.002 ↗
6. 10.1002/anie.20240235310.1002/anie.202402353 ↗
7. 10.3390/metabo1206056410.3390/metabo12060564 ↗
8. Yuan H. · J. Neurotraum. · 2022 · 41 · 11
9. 10.3390/ijms2114490810.3390/ijms21144908 ↗
10. 10.1038/s41418-022-00941-010.1038/s41418-022-00941-0 ↗
11. 10.1016/j.redox.2021.10213110.1016/j.redox.2021.102131 ↗
12. 10.1016/j.redox.2015.09.00510.1016/j.redox.2015.09.005 ↗
13. 10.1016/j.ccr.2023.21543210.1016/j.ccr.2023.215432 ↗
14. 10.1002/anie.20200595910.1002/anie.202005959 ↗
15. 10.1002/anie.20242413110.1002/anie.202424131 ↗
16. 10.1074/jbc.M117.79741510.1074/jbc.M117.797415 ↗
17. 10.1016/j.snb.2022.13270710.1016/j.snb.2022.132707 ↗
18. Zhao Y.‐Y. · J. Am. Chem. Soc. · 2025
19. 10.1021/acs.analchem.2c0223510.1021/acs.analchem.2c02235 ↗
20. 10.1021/acs.analchem.4c0512010.1021/acs.analchem.4c05120 ↗
21. 10.1016/j.snb.2022.13295910.1016/j.snb.2022.132959 ↗
22. 10.1016/j.heares.2004.02.00210.1016/j.heares.2004.02.002 ↗
23. 10.3389/fphar.2025.144657410.3389/fphar.2025.1446574 ↗
24. Hao L. · Chem. Biol. Drug Des. · 2024 · 103
25. 10.1053/jhep.2002.3202810.1053/jhep.2002.32028 ↗
26. 10.1002/hep.2312110.1002/hep.23121 ↗
27. 10.1002/anie.20241837810.1002/anie.202418378 ↗
28. 10.1016/j.ccr.2022.21481810.1016/j.ccr.2022.214818 ↗
29. 10.1002/anie.20161202010.1002/anie.201612020 ↗
30. 10.1002/anie.20240409310.1002/anie.202404093 ↗
31. Ding Y. · Adv. Sci. · 2025 · 1210.1002/advs.71431 ↗
32. 10.1002/anie.20231586110.1002/anie.202315861 ↗
33. 10.1002/ange.20240684310.1002/ange.202406843 ↗
34. 10.1021/acs.chemrev.3c0057310.1021/acs.chemrev.3c00573 ↗
35. 10.1021/acs.accounts.2c0064310.1021/acs.accounts.2c00643 ↗
36. Hao L. · Chem. Commun. · 2025
37. 10.1002/anie.20251381510.1002/anie.202513815 ↗
38. 10.1021/acs.analchem.5c0048210.1021/acs.analchem.5c00482 ↗
39. 10.1007/s11426-024-2361-x10.1007/s11426-024-2361-x ↗
40. 10.1002/advs.20240900710.1002/advs.202409007 ↗
41. 10.1021/cbmi.3c0007110.1021/cbmi.3c00071 ↗
42. 10.1002/ange.20230976810.1002/ange.202309768 ↗
43. 10.1002/anie.20230151810.1002/anie.202301518 ↗
44. 10.1002/advs.20240271010.1002/advs.202402710 ↗
45. 10.1016/j.carbpol.2021.11864410.1016/j.carbpol.2021.118644 ↗
46. 10.1002/anie.20240253710.1002/anie.202402537 ↗
47. 10.1016/j.snb.2025.13758110.1016/j.snb.2025.137581 ↗
48. 10.1021/acs.analchem.2c0571310.1021/acs.analchem.2c05713 ↗
49. 10.1016/j.intimp.2019.10603710.1016/j.intimp.2019.106037 ↗
50. 10.3390/ijms2105165110.3390/ijms21051651 ↗
51. 10.1002/hep.3167810.1002/hep.31678 ↗
52. 10.1021/jacs.4c1709210.1021/jacs.4c17092 ↗
53. 10.1002/anie.20201495910.1002/anie.202014959 ↗
54. 10.1002/anie.20210416310.1002/anie.202104163 ↗
55. 10.1016/j.chembiol.2020.03.01410.1016/j.chembiol.2020.03.014 ↗
56. 10.1002/anie.20241487910.1002/anie.202414879 ↗
57. 10.1038/s41420-021-00660-410.1038/s41420-021-00660-4 ↗
58. 10.1038/s41418-022-00970-910.1038/s41418-022-00970-9 ↗
59. 10.1038/cdd.2015.15810.1038/cdd.2015.158 ↗
60. 10.1002/anie.20250219510.1002/anie.202502195 ↗
61. 10.1016/j.bbrc.2020.09.14010.1016/j.bbrc.2020.09.140 ↗
62. 10.1016/j.freeradbiomed.2024.06.01410.1016/j.freeradbiomed.2024.06.014 ↗